{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:53:59Z","timestamp":1759452839018,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtct.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:31:56Z","timestamp":1727202716000},"page":"939-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Picking the best mismatched donor in the age of posttransplant cyclophosphamide"],"prefix":"10.1016","volume":"30","author":[{"given":"Dennis L.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2024.09.003_bib0001","doi-asserted-by":"crossref","first-page":"909.e1","DOI":"10.1016\/j.jtct.2024.07.005","article-title":"Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations","volume":"30","author":"Mehta","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2024.09.003_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2024.09.003_bib0003","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.09.003_bib0004","unstructured":"Bolon YTA-J, M., Estrada-Merly N, Lee SJ. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2024."},{"key":"10.1016\/j.jtct.2024.09.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00184","article-title":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2024.09.003_bib0006","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT","volume":"143","author":"Sanz","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.003_bib0007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.003_bib0008","article-title":"Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort","author":"Hammami","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.003_bib0009","article-title":"Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 16","key":"10.1016\/j.jtct.2024.09.003_bib0010","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1200\/JCO.2024.42.16_suppl.6503","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation (abstract)","volume":"42","author":"Al Malki","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.003_bib0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2024.09.003_bib0012","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.003_bib0013","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-Blood Transplantation in Patients with Minimal Residual Disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jtct.2024.09.003_bib0014","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.003_bib0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.003_bib0016","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","article-title":"Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant","volume":"7","author":"Perez-Valencia","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.003_bib0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41409-023-02131-z","article-title":"Post-transplantation cyclophosphamide is associated with increased bacterial infections","volume":"59","author":"Ustun","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.003_bib0018","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/bloodadvances.2023011625","article-title":"Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T18:04:52Z","timestamp":1759428292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666636724006286"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Picking the best mismatched donor in the age of posttransplant cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}